Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2787-2799

  Mendelsohn, John ^a   Baselga, Jose ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER MODEL; CANCER RESEARCH; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CARCINOMA; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; CELL TRANSFORMATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; MALE; METHODOLOGY; NEOPLASM; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS, PHASE III; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; MALE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 0041629450     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.504     Document Type: Review

References (100)

1. Yarden Y, Sliwkowski M: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
2. Klapper L, Waterman H, Sela M, et al: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384-3388, 2000
3. Olayioye M, Neve R, Lane H, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000
4. Kuan CT, Wikstrand CJ, Bigner DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96, 2001
5. Prenzel N, Zwick E, Daub H, et al: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884-888, 1999
6. Liu D, Ghiso JA, Estrada Y, et al: EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1:445-457, 2002
7. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000
8. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83-86, 1997
9. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139, 1998
10. Chan TO, Rittenhouse SE, Tsichlis PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 68:965-1014, 1999
11. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489-501, 2002
12. Kawamoto T, Sato JD, Le A, et al: Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 80:1337-1341, 1983
13. Sato JD, Kawamoto T, Le AD, et al: Biological effect in vitro of monoclonal antibodies to human EGF receptors. MoI Biol Med 1:511-529, 1983
14. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
15. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1s-13s, 2002 (suppl 18)
16. Salomon D, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
17. Moscatello DK: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539, 1995
18. Nishikawa R: A mutant epidermal growth factor receptor common in human gltoma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91:7727-7731, 1994
19. Grandis JR, Meinem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
20. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53:2379-2385, 1993
21. Rodeck U, Herlyn M, Herlyn D, et al: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res 47:3692-3696, 1987
22. Aboud-Pirak E, Hurwitz E, Pirak ME, et al: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611, 1988
23. Azemar M, Schmidt M, Arlt F, et al: Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid regression in vivo. Int J Cancer 86:269-275, 2000
24. Ciardiello F, Caputo R, Troiani T, et al: Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93:172-178, 2001
25. Yamazaki H, Kijima H, Ohmishi Y, et al: Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 90:581-587, 1998
26. Jannot CB, Beerli RR, Mason S, et al: Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 13:275-282, 1996
27. Gill GN, Kawamoto T, Cochet C, et al: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259:7755-7760, 1984
28. Fan Z, Lu Y, Wu X, et al: Antibody-induced epidermal growth factor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269:27595-27602, 1994
29. Arteaga CL, Ramsey TT, Shawver LK, et al: Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272:23247-23254, 1997
30. Lichtner RB, Menrad A, Sommer A, et al: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61:5790-5795, 2001
31. Fry D: Site-directed irreversible inhibitors of the erbB family tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 15:3-16, 2000
32. Lal A, Glazer CA, Martinson HM, et al: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335-3339, 2002
33. Busse D, Doughty R, Ramsey T, et al: Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275:6987-6995, 2000
34. Albanell J, Codony-Servat J, Rojo F, et al: Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-EGF receptor treatments. Cancer Res 61:6500-6510, 2001
35. Anido J, Matar P, Albanell J, et al: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpression breast cancer cells. Clin Cancer Res 9:1274-1283, 2003
36. Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001
37. Normanno N, Campiglio M, De Luca A, et al: Cooperative inhibitory effect of ZD1839 ("Iressa") in combination with trastuzumab ("Herceptin") on human breast cancer cell growth. Ann Oncol 13:65-72, 2002
38. Moulder SL, Yakes M, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZDI839 (Iressa) inhibits HER2/Neu (erb-2)- overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
39. Bromberg J, Wrzeszczynska M, Devgan G, et al: Stat3 as an oncogene. Cell 98:295-303, 1999
40. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-1403, 1996
41. Peng D, Fan Z, Lu Y, et al: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56:3666-3669, 1996
42. Moyer JD, Barbacci ES, Iwata KT, et al: Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tysosine kinase. Cancer Res 57:4838-4848, 1997
43. Budillon A, Di Gennaro E, Barbarino M, et al: ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27Kip1 inducing Gl arrest and enhancing the antitumor effect of interferon alpha. Proc Am Assoc Cancer Res 41:4910, 2000 (abstr)
44. Wu X, Fan Z, Masui H, et al: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905, 1995
45. Mandal M, Adam L, Mendelsohn J, et al: Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 17:999-1007, 1998
46. Liu B, Fang M, Schmidt M, et al: Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 82:1991-1999, 2000
47. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
48. Perrotte P, Matsumoto T, Inoue K, et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-264, 1999
49. Bruns CJ, Solorzano CC, Harbison MT, et al: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926-2935, 2000
50. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001
51. O-charoenrat P, Modjtahedi H, Rhys-Evans P, et al: Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60:1121-1128, 2000
52. O-charoenrat P, Rhys-Evans P, Court W, et al: Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clin Exp Metastasis 17:631-639, 1999
53. Matsumoto T, Perrotte P, Bar-Eli M, et al: Blockade of EGF-R signaling with anti-EGFR monoclonal antibody (Mab) C225 inhibits matrix metalloproteinase-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo. Proc Am Assoc Cancer Res 39:83, 1998 (abstr)
54. Baselga J, Norton L, Masui H, et al: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993
55. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-EGF receptor monoclonal antibodies plus cis-Diaminedichloroplatinum (cis-DDP) on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
56. Baselga J, Norton L, Coplan K, et al: Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res 35:2262, 1994 (abstr)
57. Ciardiello F, Bianco R, Damiano V, et al: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor antibody. Clin Cancer Res 5:909-916, 1999
58. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
59. Sirotnak FM, Zakowsky MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenographs is markedly enhanced by coadministration of ZD1839 ('Iressa') an inhibitor of tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
60. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
61. Williams K, Telfer B, Stratford I, et al: Combination of ZD1839 ('Iressa'), an EGFR tyrosine kinase inhibitor, and radiotherapy increases antitumor efficacy in a human colon cancer xenograft model. Proc Am Assoc Cancer Res 42:3840, 2001 (abstr)
62. Naramura M, Gillies SD, Mendelsohn J, et al: Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37:343-349, 1993
63. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446, 2000
64. Bos M, Mendelsohn J, Kim YM, et al: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 3:2099-2106, 1997
65. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318, 1995
66. Cohen R, Falcey JW, Paulter VJ, et al: Safety profile of the monoclonal antibody (MOAB) IMC-C225, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors. Proc Am Soc Clin Oncol 19:474a, 2000 (abstr 1862)
67. Khazaeli MB, LoBuglio AF, Falcey JW, et al: Low immunogenicity of a chimeric monoclonal antibody (MOAB), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. Proc Am Soc Clin Oncol 19:207a, 2000 (abstr 808)
68. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
69. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001
70. Rubin M, Shin D, Pasmantier M, et al: Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol 19:474a, 2000 (abstr 1860)
71. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:7A, 2001 (abstr)
72. Saltz L, Rubin M, Hochster H, et al: Acne-like rash predicts response in patients ,treated with cetuximab (IMC-225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer that expresses EGFR. Proc AACR-NCI-EORTC. J Clin Invest 68:559, 2001 (suppl, abstr)
73. Hong WK, Arquette M, Nabell L, et al: Efficacy and safety of the anti-epidermal growth factor antibody IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 20:895, 2001 (abstr)
74. Baselga J, Trigo JM, Bourthis J, et al: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum based agent. Proc Am Soc Clin Oncol 21:900, 2002 (abstr)
75. Saltz L, Meropol NJ, Loehrer PJ, et al: Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21:504, 2002 (abstr)
76. Burtness BA, Li Y, Flood W, et al: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 21:901, 2002 (abstr)
77. Abbruzzese JL, Rosenberg A, Xiong Q, et al: Phase II study of anti-epidermal growth factor receptor (EGFr) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 20:518, 2001 (abstr)
78. Kim ES, Mauer AM, Fossella FV, et al: A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21, 2002 (abstr 1168)
79. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243, 2001
80. Yang X-D, Jia X-C, Corvalan JRF, et al: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59:1236-1243, 1999
81. Schwartz G, Dutcher JP, Vogelzang NJ, et al: Phase II clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 21:91, 2002 (abstr)
82. Tewes M, Schleucher N, Dirsch O, et al: Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors. Proc Am Soc Clin Oncol 21:378, 2002 (abstr)
83. Tabernero J, Rojo F, JimÈnez E, et al: A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR. Eur J Cancer 38:69, 2002 (suppl 7, abstr)
84. Crombet T, Osorio M, Cruz T, et al: Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer. Proc Am Soc Clin Oncol 21:53, 2002 (abstr)
85. Negri DR, Tosi E, Valota O, et al: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab′)2 bispecific monoclonal antibody. Br J Cancer 72:928-933, 1995
86. Curnow RT: Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 45:210-215, 1997
87. Pfister DG, Lipton A, Belt R, et al: A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. Proc Am Soc Clin Oncol 18:433a, 1999 (abstr 1667)
88. Goldstein J, Graziano RF, Sundarapandiyan K, et al: Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) × epidermal growth factor bispecific fusion protein. J Immunol 158:872-879, 1997
89. Woodburn JR, Barker AJ, Gibson KH, et al: ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Am Assoc Cancer Res 38:4521, 1997 (abstr)
90. Woodburn J, Kendrcw J, Fennell M, et al: ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc Am Assoc Cancer Res 41:2552, 2000 (abstr)
91. Ferry D, Hammond L, Ranson M, et al: Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study. Proc Am Soc Clin Oncol 19:5E, 2000 (abstr)
92. Nakagawa K, Yamamoto N, Kudoh S, et al: A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumors. Proc Am Soc Clin Oncol 19:711, 2000 (abstr)
93. Baselga J, Herbst R, LoRusso P, et al: Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Am Soc Clin Oncol 19:686, 2000 (abstr)
94. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the EGF receptor inhibitor ZD1839 (Iressa) in skin from cancer patients: Histopathological and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002
95. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21, 2002 (abstr 1188)
96. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21, 2002 (abstr 1166)
97. Miller V, Johnson D, Heelan R, et al: A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:326a, 2001 (abstr 1301)
98. Giaccone G, Gonzales-Larriba J, Smit E, et al: ZD1839 (Iressa), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: Preliminary tolerability, efficacy and pharmacokinetic results. Eur J Cancer 37:102, 2001 (suppl 6, abstr)
99. Giaccone G, Johnson D, Manegold C, et al: A phase III trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 5:40, 2002 (suppl, abstr)
100. Johnson D, Herbst R, Giaccone G, et al: ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2). Ann Oncol 5:468, 2002 (suppl, abstr)